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Abstract: After more than 40 years of clinical use, levodopa (LD) remains the gold standard of 
symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other 
available dopaminergic therapies, dopamine replacement with LD is associated with the greatest 
improvement in motor function. Long-term treatment with LD is, however, often complicated 
by the development of various types of motor response oscillations over the day, as well as 
drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as 
entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa or dopamine, 
respectively. However, dyskinesia control still represents a major challenge. As a result, many 
neurologists have become cautious when prescribing therapy with LD. This review summarizes 
the available evidence regarding the use of LD to treat PD and will also address the issue of LD 
delivery as a critical factor for the drug’s propensity to induce motor complications.
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Introduction
After more than 40 years of clinical use, levodopa (LD) remains the gold standard 
regarding symptomatic efficacy in the drug treatment of Parkinson’s disease (PD).1 
Compared with other available dopaminergic therapies, dopamine replacement with LD 
is associated with the greatest improvement in motor function, as assessed by reduced 
scores in the Unified Parkinson’s Disease Rating Scale [UPDRS]).2–5 In   addition, 
responsiveness to LD (required to exceed 25%–30% reduction in the motor part of the 
UPDRS) is a diagnostic criterion for PD.6 In clinical practice, LD slows the   progression 
of disability as assessed by the Hoehn and Yahr staging system,7 and is associated with 
a reduction in mortality.8,9 Importantly, LD is one of the best tolerated drugs to treat 
PD, particularly in the elderly population.10
However, long-term treatment with LD is often complicated by the development 
of various types of motor response oscillations over the day as well as drug-induced 
dyskinesia, a complication characterized by erratic involuntary movements. Such treat-
ment-related motor complications eventually develop in the majority of patients and are 
found in about one-third of patients after only two years of exposure.11 Once established, 
motor complications are difficult to treat and can develop into a significant source of 
disability. In extreme cases, treatment-induced dyskinesias may completely annihilate 
the therapeutic benefit initially gained from the drug. Concerns about the potential 
induction of long-term motor complications have led many physicians to use LD in a 
restricted manner and reserve it as a second-line strategy. This approach has gained wide 
acceptance following clinical trials in early PD, showing significantly reduced risks Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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of developing motor complications with   dopamine agonists 
(DAs) as compared with LD monotherapy.2–5 While these 
trials have indeed established the potential of DAs to delay 
the onset of motor complications, they have also consistently 
demonstrated the superior symptomatic efficacy of LD, with 
a need for LD supplementation within the first 2–3 years in 
most patients started on a DA.2
Despite such evidence from clinical trials of the need for 
LD supplementation to maintain symptomatic control in early 
PD, in general clinical practice, LD is often withheld beyond 
the time when symptomatic control with DAs has become 
insufficient.12 This results, in part, from patient perceptions. 
Information gleaned from physicians or the media may alert 
patients to the risk of dyskinesia associated with LD. The 
alarming nature of dyskinesia can, in turn, lead to a phenom-
enon labeled “dopa-phobia”.12 These concerns have even 
been extrapolated to using single doses of LD in challenge 
tests, in order to prime the striatum putatively for subsequent 
dyskinetic responses to dopaminergic therapies.13
Increasing evidence now suggests that motor   complications 
(particularly dyskinesia) associated with sustained LD 
  therapy are a result of discontinuous and intermittent   delivery 
of LD to the brain, resulting in nonphysiologic pulsatile 
  stimulation of striatal dopamine receptors. Thus, the short 
half-life (90   minutes) of immediate-release LD formulations 
is thought to be the key factor in the pathogenesis of motor 
complications, rather than their induction being an intrinsic 
property of the LD molecule.1 This review will summarize the 
available evidence regarding the use of LD to treat PD and 
will also address the issue of LD delivery as a critical factor 
for the drug’s propensity to induce motor complications.
Efficacy of levodopa in early 
Parkinson’s disease
There have been a number of large-scale, long-term, LD- 
controlled monotherapy trials of DAs in early Parkinson’s 
disease on which strong conclusions about the relative effect 
size of LD compared with DAs can be based. The   four-year 
randomized Comparison of the Agonist Pramipexole versus 
Levodopa on Motor Complications of Parkinson’s Disease 
(CALM-PD) trial, compared initial treatment with pramipex-
ole (0.5 mg three times daily) versus LD-carbidopa (100/25 mg 
three times daily), followed by open-label LD supplementation 
as required.2 The primary outcome measure was the time to first 
occurrence of dopaminergic complications, which included 
wearing-off (the re-emergence of PD symptoms due to the 
diminishing effect of LD), dyskinesias, “on–off” fluctua-
tions (unpredictable fluctuations varying between symptoms 
being well controlled [on] to uncontrolled [off]), and freezing. 
  Secondary outcome measures were changes in UPDRS scores 
and quality of life. Although initial treatment with   pramipexole 
resulted in lower incidences of dyskinesia and wearing-off 
compared with initial treatment with LD, symptom control, 
as assessed by the UPDRS, was superior in patients treated 
with LD. From baseline to month 48, there was a worsening 
from baseline of 1.3 ± 13.3 (mean ±   standard deviation [SD]) 
points in UPDRS motor scores in the pramipexole group 
compared with an   improvement of 3.4 ± 12.3 points in the 
LD group (treatment difference of 4.9 points, P = 0.001) as 
shown in Figure 1A.
Interestingly, even though physicians in this trial had 
the option to use open-label LD supplementation to enhance 
symptomatic control, the group differences observed in the 
UPDRS motor and activities of daily living   components 
between patients randomized to pramipexole or LD remained 
relatively uniform throughout the four years of the study. 
It is not definitely established why the UPDRS scores of 
the pramipexole group never caught up with the LD group, 
despite the option of open-label LD and other antiparkin-
sonian therapies, but it might be related to the lower dose 
of LD used in the supplemented pramipexole patients 
(434 ± 498 mg/day) compared with those on LD monotherapy 
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Figure 1 Mean ± standard deviation change from baseline in A) Unified Parkinson’s 
Disease Rating Scale (UPDRS) motor scores during the course of the five-year 056 
and four-year comparison of the CALM-PD (Comparison of Agonist Pramipexole 
versus Levodopa on Motor Complications of Parkinson’s Disease) trials by treatment 
assignment. B) Percentage of patients receiving monotherapy with dopamine agonists 
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(702 ± 461 mg/day). Indeed, the calculated LD equivalent 
dose used in the supplemented pramipexole patients falls 
in the range of 468–584 mg/day, which is notably less than 
the 702 ± 461 mg/day dose used in patients initiated on LD 
monotherapy. This indicates that combined treatment with a 
lower dose of LD and a DA is not equivalent to higher dose 
LD monotherapy in terms of symptomatic control, calling 
into question the concept of LD-equivalent doses of DAs.
In the five-year 056 study, which compared the safety 
and efficacy of ropinirole with that of LD, the primary effi-
cacy measure was the occurrence of dyskinesia.3 Ropinirole 
was initiated at 0.25 mg three times daily and increased 
weekly, as necessary, up to a maximum dose of 8 mg three 
times daily. Levodopa was initiated at a dose of 50 mg once 
daily and increased weekly, as necessary, to a maximum 
of 400 mg three times daily. As in the CALM-PD study, if 
symptoms were not adequately controlled by the assigned 
study medication, patients could receive supplementary LD, 
administered in an open-label fashion. In this study, 84% 
of all patients initiated on ropinirole monotherapy either 
required LD   supplementation (427 ± 221 mg/day) or 
dropped out of the study. Although this study demonstrated 
a reduced incidence of dyskinesia for ropinirole versus LD 
(20% versus 45%, respectively), this benefit was once again 
found to be at the expense of symptomatic control. In those 
patients who completed the study, there was a minimal 
improvement from baseline of 0.8 ± 10.1 points in UPDRS 
motor scores in the ropinirole group, contrasting with an 
improvement of 4.8 ± 8.3 points in the LD group (Figure 1A). 
Similar results confirming the superior efficacy of LD (in 
terms of UPDRS motor scores) were also observed in the 
two-year   REAL-PET (ReQuip as Early Therapy versus 
L-dopa–Positron Emission Tomography) study of LD versus 
ropinirole monotherapy.14
The clinical relevance of such differences in UPDRS 
scores has been debated, but is vividly illustrated by the 
increasing rates of supplementation with open-label LD over 
the course of these double-blind comparative trials. At four 
years’ follow-up in the CALM-PD trial, 72% of patients ran-
domized to pramipexole monotherapy had required add-on 
LD to maintain symptomatic control, and this figure was 66% 
after five years in the 056 study with ropinirole (Figure 1B).2–5 
The term “LD rescue”, commonly used in this context, aptly 
describes the role of LD as the most   efficacious drug at hand 
to control motor symptoms when other drugs begin to fail.
The recently published PELMOPET (Pergolide versus 
L-dopa Monotherapy and Positron Emission Tomography) 
study5 employed a strict pergolide (0.75–5.0 mg/day) and LD 
(150–1200 mg/day) monotherapy design in which no rescue 
therapy was allowed. At one year, there was a relatively small 
difference in favor of LD in the mean change from baseline in 
UPDRS motor scores (-3.2 points in the pergolide treatment 
group compared with -5.2 points in the LD treatment group). 
However, after three years of monotherapy, patients receiv-
ing pergolide had deteriorated below baseline by 2.8 ± 9.8 
points, whereas patients receiving LD were still improved 
by 2.8 ± 7.8 points.
Taken together, these LD-controlled trials of DA 
monotherapy in early PD clearly show the need for LD 
supplementation to maintain symptomatic control.
Delaying dyskinesias using initial 
monotherapy with dopamine 
agonists
Current recommendations to initiate dopaminergic therapy 
in early PD with a DA, or even a monoamine oxidase 
inhibitor, are chiefly based on concerns about the evolu-
tion of motor complications characteristic of sustained LD 
therapy, most notably drug-induced dyskinesias. While the 
monotherapy trials cited above have clearly established a 
reduced dyskinesia risk with DA monotherapy, they have 
also shown that this is exclusively due to the delay in start-
ing patients on LD. Indeed, PD patients initiated on a DA in 
these trials eventually required supplemental LD in order to 
maintain symptomatic control, and developed dyskinesias 
at an identical rate (albeit with a delay) to those started on 
LD, leading to steady increases in dyskinesia rates from 
this point onwards.15 Therefore, the question remains as to 
whether the initial benefit of reduced motor complication 
rates can be maintained in the longer term when virtually all 
patients will be on combined drug treatment with DAs, LD, 
and possibly other agents. While none of the aforementioned 
comparative trials has been designed to assess outcomes 
under double-blind conditions for longer than five years, 
longer term, open-label, follow-up data are available. The 
Parkinson Study Group recently reported on the six-year 
outcomes of patient groups initially randomized to receive 
monotherapy with pramipexole or LD in the CALM-PD 
trial. Results of this study showed a persistent, statistically 
significant difference in overall dyskinesia rates of about 
37% in those randomized to initial LD compared with 20% 
in those initiated on pramipexole (P = 0.004).16 Despite this, 
90% of the population followed were on LD by six years.16 
Similarly, 10-year outcomes reported by Lees et al17 com-
paring initial monotherapy with bromocriptine versus LD, 
along with Hauser et al18 from the 056 ropinirole study, also Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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demonstrated a reduced overall incidence of dyskinesias 
with DAs in the long term. After 10 years, 45% of patients 
who were initiated with bromocriptine had dyskinesias com-
pared with 54% of those started on LD (corresponding to an 
incidence rate for first dyskinesia occurrence of 145.3 versus 
105.9 per 1000 patient-years after starting treatment with LD 
or DA, respectively).17 Similar figures were reported for the 
10-year follow-up of patients of the 056 study of ropinirole 
versus LD (52.4% versus 77.8%, P = 0.0457).19
While these results convincingly show long-term reduc-
tions in the incidence of dyskinesia with DAs compared with 
LD, rates of dyskinesia do not necessarily reflect differences in 
dyskinesia-related disability between treatments. Hauser et al20 
were the first to demonstrate differential functional significance 
of dyskinesias by asking patients to rate their involuntary 
movements as “troublesome” or “nontroublesome” in a modi-
fied “on/off” diary. When patients were subsequently asked to 
rate their recorded “on” or “off” times as functionally “good” 
or “bad” periods, 93.8% of “on” time with nontroublesome 
dyskinesia was considered functionally “good” time, whereas 
84.9% of “off” time and 89.9% of “on” time with troublesome 
dyskinesia was considered “bad” time.20
In this respect, it is interesting to note that, at 10 and 
14 years, respectively, neither the ropinirole nor bromocrip-
tine studies found significant differences between treatment 
arms in the emergence of disabling dyskinesia.15,17,21 This 
finding was also observed in the CALM-PD study at four 
years, where the rate of disabling dyskinesias was low in 
patients treated with either pramipexole or LD.16 In addition, 
the recent STRIDE-PD (Stalevo Reduction In Dyskinesia 
Evaluation) trial comparing time to dyskinesia development 
in patients treated with either standard LD or a fixed combi-
nation of LD, carbidopa, and entacapone showed a less than 
10% incidence of disabling dyskinesias in both groups.22
Furthermore, patient surveys have also indicated that 
patients with dyskinesias are less concerned about their 
dyskinesias than those who have not yet experienced dys-
kinesias, and that more than 80% of these patients prefer 
having dyskinesia over their PD symptoms.23 Since patients 
often tolerate mild dyskinesia well, the risk of dyskinesia 
should not cause physicians to delay LD initiation in patients 
whose PD symptoms cannot be sufficiently controlled with 
other treatments, regardless of patient age. Given these 
findings, the decision to initiate LD must be tailored to the 
patient’s needs and should include proper counseling about 
the impact of dyskinesia and current options to minimize 
their incidence, including cautious LD dosing, or to treat 
them once they are present.
Tolerability and safety issues
In routine clinical practice, the benefits and risks of any 
anti-PD therapy must be weighed before prescribing the 
medication. LD therapy is generally well tolerated, and acute 
side effects include nausea, vomiting, and hypotension.24,25 
As such, LD is generally started at a low dose to minimize 
these risks. With chronic use, the most common complica-
tions include wearing-off and dyskinesia, which can be 
troublesome for the patient (Figure 2).26 However, while 
the use of DAs is not associated with motor complications, 
a different array of side effects, including hallucinations, 
somnolence, and edema, are observed more commonly with 
these anti-PD medications (Figure 2). Dopamine agonists 
have also been linked to impulse-control disorders, such 
as pathologic gambling, hypersexuality, binge eating, or 
pathologic shopping, with about 13.7%–17.1% of patients 
on DA therapy showing signs of such disorders.27–29 While 
some of the adverse events associated with DA therapy are 
often perceived to be less bothersome for patients than LD-
induced motor complications, others such as impulse-control 
disorders and sleep attacks, can have serious consequences 
for both the patient and their social relationships such that 
the advantages of delaying LD-associated risks by treatment 
with DAs may be negated. Therefore, the choice of therapy 
should be an individualized decision that takes into account 
the differential risk profiles of the various DA replacement 
strategies.
Levodopa and progression  
of Parkinson’s disease
Another perceived risk of LD that still causes concern 
among many neurologists is related to its effect on   disease 
Dyskinesia
Motor fluctuations
Dopamine dysregulation syndrome
Edema
Somnolence
Impulse control disorders
Hallucinations
Nausea
Fibrosis*
Higher risk with
levodopa
Higher risk with
dopamine agonists
Figure 2 Comparison of the risk of motor complications and other adverse events 
associated with levodopa versus dopamine agonists. The length of the arrow reflects 
the extent of risk. 
Note: *Ergot-derived dopamine agonists compared with levodopa.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
233
Rethinking levodopa in Parkinson’s disease
progression. In the early 1990s, a number of in vitro   studies 
  demonstrated that high doses of LD can be toxic to dopamin-
ergic neurons in cell culture,30–32 causing some PD specialists 
to recommend withholding LD for as long as   possible.33 
Since that time, data have accumulated   showing that LD 
may also have protective effects for cultured dopamine 
neurons, depending on experimental conditions, such as 
presence or absence of glia34,35 or ascorbic acid,36,37 as well as 
LD dose used.38 In addition, many in vivo studies could not 
find evidence of LD-induced neurodegeneration in normal 
rodents,39 primates,40 and nonparkinsonian humans,41 and 
some have even reported neuroprotective effects of LD on 
midbrain dopaminergic neurons.42,43 Of particular interest 
are pathology reports from patients with essential tremor or 
dopa-responsive dystonia who had been chronically exposed 
to large amounts of LD over many years. None of these 
patients have shown evidence of substantia nigra degenera-
tion at autopsy.8,9,44
After almost 40 years of established clinical use, the Par-
kinson Study Group recently conducted the first high-quality, 
randomized, placebo-controlled trial of LD to define better 
the effects of LD monotherapy on clinical progression in early 
PD.45 The ELLDOPA (Earlier versus Later Levodopa) study 
included 361 patients with early PD who were randomized to 
receive LD–carbidopa at a daily dose of 150/37.5 mg, 300/75 
mg, or 600/150 mg, respectively, or a matching placebo for a 
period of 40 weeks. The primary outcome was the difference 
in UPDRS scores between treatment groups at week 42 after 
withdrawal of treatment for two weeks. This endpoint was 
chosen to detect any potential underlying effect of active 
treatment on PD progression, with the assumption that a 
two-week washout period would remove all symptomatic 
LD effects, and any remaining differences in UPDRS scores 
between groups by this time would reflect treatment effects 
on disease progression. In addition, assessments of striatal 
dopamine transporter density using iodine-123-labeled 
2-β-carboxymethoxy-3-β-(4-iodophenyl)tropane ([123I] 
β-CIT) single photon emission computed tomography were 
performed at baseline and at the end of study as a surrogate 
measure of progression of nigrostriatal terminal dysfunction. 
After a two-week washout period, the UPDRS motor scores 
in each group of LD-treated patients were still significantly 
improved compared with patients on placebo. This not only 
seems to exclude any evidence for negative effects of LD 
on the progression of PD but, on the contrary, suggests that 
treatment with LD results in a decline of UPDRS scores over 
time as compared with placebo.   Nevertheless, there remains 
a possibility that a two-week washout could be insufficient 
for symptomatic effects of LD to wear off completely, thus 
precluding firm conclusions about the disease-modifying 
efficacy of LD from this study. Adding to this uncertainty, 
there was a significantly greater decline of striatal β-CIT 
binding in the high-dose arm of this trial compared with 
placebo in patients with abnormal scans at baseline. Interpre-
tation of this finding is again confounded by the possibility 
of regulatory effects of LD on dopamine transporter binding 
or expression.
Integrating the currently available evidence from experi-
mental studies and clinical trials, there is very little reason 
to assume that LD might hasten the clinical progression of 
PD, and withholding the drug because of such fears from 
patients in clinical need of optimized symptomatic control 
is not warranted. Accordingly, US and European PD prac-
tice guidelines consistently recommend early use of LD 
in patients requiring initiation of dopaminergic treatment 
when the perceived dyskinesia risk is low, as is the case in 
the elderly.46
Challenge of optimizing  
levodopa delivery
The mechanism of action of LD is related to its activity as 
a prodrug for central dopamine and involves a number of 
critical steps, including gastrointestinal absorption, passage 
across the blood–brain barrier, neuronal uptake, and conver-
sion to dopamine via enzymatic action of aromatic amino 
acid decarboxylase (AADC) (Figure 3), and eventually 
synaptic release of dopamine thus generated from exogenous 
LD. This sequence of events, needed for LD to exert its 
antiparkinsonian effect, is subject to a number of interfering 
processes, which can contribute to dose failures and long-
term complications.47 These include delayed gastric emptying 
and altered absorption of LD due to a competitive effect 
with ingested proteins at the level of amino acid transport-
ers located in the gastrointestinal tract and the blood–brain 
barrier. Two major peripheral LD metabolic pathways, driven 
by the enzymes AADC and catechol-O-methyl transferase, 
significantly deplete the amount of LD reaching the brain. In 
addition, the short half-life (36–96 minutes) of LD is asso-
ciated with fluctuating LD plasma levels, which eventually 
translate into fluctuating levels of synaptic dopamine derived 
from exogenous LD.47 Consequently, for optimal benefit, LD 
has to be administered as multiple daily doses, but conven-
tional three times daily regimens have not been found to be 
sufficient to establish constant plasma levels.48
In the earlier stages of the disease, oscillations in 
plasma levels are not clearly associated with fluctuations in Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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motor function, presumably due to central “buffering” via 
  intraneuronal storage in surviving nigrostriatal terminals, 
providing continuous stimulation even in the context of 
discontinuous exogenous delivery (Figure 4). However, with 
progressive loss of nigrostriatal terminals and   accompanying 
changes in the central pharmacodynamics of LD, the clinical 
response to individual doses becomes progressively short-
lived, resulting in wearing-off and “on-off”-type motor 
fluctuations. These motor fluctuations can be completely 
abolished by continuous intravenous infusions of LD,48 
supporting the concept that providing a less pulsatile, more 
continuous, striatal dopamine receptor stimulation may be 
critical to restoring physiological motor processing in the 
striato-pallido-thalamo-cortical network in PD.49–53
The issue of continuous drug delivery is also relevant 
to the current understanding of mechanisms underlying the 
development of LD-induced dyskinesia. In animal models of 
PD, administration of D1 or D2 agonists with short half-lives 
is associated with dyskinetic responses,54–57 while exposure 
to long-acting agonists does not induce dyskinesia.58–60 
The same differences have also been observed in studies 
comparing pulsatile versus continuous delivery of the same 
dopaminergic agent.61,62 Such results are consistent with 
clinical studies of continuous infusions of DAs, such as 
apomorphine63,64 or lisuride,65 which were found to downregu-
late pre-existing LD-induced dyskinesia. Indeed, when given 
as continuous intraduodenal infusions, marked   reductions in 
dyskinesia have been reported for LD itself49,53,66,67 and the 
gel preparation of LD (Duodopa®, Solvay Pharmaceuticals 
GmbH).68,69
Although pulsatile stimulation may not be sufficient to 
explain the mechanisms underlying the induction of dyski-
nesia completely, such observations highlight the need to 
optimize LD delivery in PD. The use of intravenous infusions 
is not feasible for chronic treatment, and intrajejunal infusion 
strategies are currently limited by high costs and the need for 
percutaneous gastrostomy. Other routes of LD delivery, eg, 
transdermal or transnasal, are currently under investigation 
but no nonenteral system has yet reached the market.58–60,70,71 
Previous attempts to improve oral delivery have included 
the development of sustained-release preparations of LD, 
but unfortunately randomized controlled studies have failed 
to reveal any difference between such formulations and 
standard LD with respect to long-term dyskinesia risk.72–74 
Sustained-release LD preparations exhibit erratic absorption 
patterns and unpredictable plasma levels,67 resulting in dose 
failures as well as a delay in producing a clinical benefit.75 
As such, the unpredictable absorption of these agents may 
not abolish high peak and low trough LD plasma levels that 
are associated with the development of dyskinesia.
Likewise, controlled trials have not clearly established 
superiority of sustained-release LD in terms of control of 
motor fluctuations.76 By contrast, prolonging the LD half-life 
via adjunctive treatment with a catechol-O-methyltransferase 
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inhibitor, such as entacapone or tolcapone, has been found 
to be efficacious in reducing daily “off” time in a number of 
well-performed, randomized, controlled trials in PD patients 
with wearing-off.77–80
The established efficacy of entacapone in PD patients 
with wearing-off has raised the possibility that it may also 
be effective in reducing the risk of dyskinesias. However, 
results of the recent STRIDE-PD trial demonstrated that, in 
patients with early PD who are not experiencing wearing-off, 
a four times daily dose of a LD formulation comprising LD, 
carbidopa, and entacapone is not superior to conventional 
LD in delaying dyskinesias.22 The study investigators have 
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proposed that entacapone may not have been administered 
frequently enough to achieve smooth levels of LD in the 
plasma.22
As such, current research is focusing on the development 
of new LD formulations and delivery systems, such as novel 
controlled-release and transdermal preparations, which may 
improve delivery of LD in order to achieve smoother LD 
plasma levels. It remains to be seen whether these new LD 
formulations will prove effective in minimizing the risk of 
drug-induced motor complications.
Conclusions
Despite all recent advances in the medical management 
of PD, LD has remained the therapeutic gold standard in 
controlling the cardinal motor features of this illness. There 
is no evidence to support withholding LD for fear of has-
tening the progression of PD, although current three times 
daily regimens of standard oral LD carry a definite risk of 
inducing potentially disabling drug-induced involuntary 
movements. While dyskinetic responses are common with 
sustained LD therapy, the proportion of patients actually 
developing disabling and severe dyskinesia has been below 
10% in a recent four-year randomized trial2 and below 20% 
in a 10-year follow-up series.17 This should be taken into 
account when the physician discusses the potential use of 
LD with the patient, particularly in patients who require 
enhanced symptomatic control despite optimized treatment 
with DAs. Moreover, when making individual decisions 
on how to initiate dopaminergic treatment, the weighing of 
relative risks and benefits of starting with a DA or LD should 
not only consider dyskinesia risks but also risks for other 
side effects, including daytime somnolence, impulse-control 
disorders and, in the case of ergot-derived DAs, cardiac 
valvulopathy and other forms of potentially life-threatening 
fibrosis.27 In addition, individual needs for magnitude and 
speed of symptomatic improvement must be balanced against 
potential side effects. For over 40 years, LD has remained the 
cornerstone of PD therapy. Future endeavors will focus on 
optimizing delivery of LD in order to expand and improve 
the treatment options of PD.
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